Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc - BRDR

BSP:VRTX34 (USA)   BRDR
R$ 519.48 (-0.3%) Mar 27
30.06
P/B:
6.12
Market Cap:
R$ 536.74B ($ 107.51B)
Enterprise V:
R$ 484.78B ($ 97.10B)
Volume:
100.00
Avg Vol (2M):
108.00
Also Trade In:
Volume:
100.00
Avg Vol (2M):
108.00

Business Description

Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Name Current Vs Industry Vs History
Cash-To-Debt 13.88
Equity-to-Asset 0.77
Debt-to-Equity 0.05
Debt-to-EBITDA 0.18
Interest Coverage 97.68
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 14.83
Distress
Grey
Safe
Beneish M-Score -2.04
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.72
9-Day RSI 51.2
14-Day RSI 49.78
6-1 Month Momentum % 21.02
12-1 Month Momentum % 32.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.99
Quick Ratio 3.78
Cash Ratio 3.16
Days Inventory 175.05
Days Sales Outstanding 56.57
Days Payable 100.11

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 0.3
Shareholder Yield % 0.69

Financials (Next Earnings Date:2024-05-01 Est.)

BSP:VRTX34's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Vertex Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 49,072.115
EPS (TTM) (R$) 17.221
Beta -0.21
Volatility % 19.55
14-Day RSI 49.78
14-Day ATR (R$) 5.657718
20-Day SMA (R$) 517.9175
12-1 Month Momentum % 32.27
52-Week Range (R$) 360.1 - 554.04
Shares Outstanding (Mil) 1,033.23

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vertex Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Vertex Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(R$)
No Event Data

Vertex Pharmaceuticals Inc Frequently Asked Questions

What is Vertex Pharmaceuticals Inc(BSP:VRTX34)'s stock price today?
The current price of BSP:VRTX34 is R$519.48. The 52 week high of BSP:VRTX34 is R$554.04 and 52 week low is R$360.10.
When is next earnings date of Vertex Pharmaceuticals Inc(BSP:VRTX34)?
The next earnings date of Vertex Pharmaceuticals Inc(BSP:VRTX34) is 2024-05-01 Est..
Does Vertex Pharmaceuticals Inc(BSP:VRTX34) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(BSP:VRTX34) does not pay dividend.

Press Release

Subject Date
No Press Release